<DOC>
	<DOCNO>NCT02578030</DOCNO>
	<brief_summary>To provide additional , required information pharmacokinetic profile SHP465 target population ( child adolescent age 6-17 year age ADHD ) .</brief_summary>
	<brief_title>Pharmacokinetic Study Children Adolescents Aged 6 17 Years Who Have Been Diagnosed With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Age 6 17 year inclusive time consent/assent . The date signature inform consent/assent define begin Screening Period . This inclusion criterion assess first screen visit . 2 . Male , nonpregnant , nonlactating female agree comply applicable contraceptive requirement protocol female nonchildbearing potential . 3 . Subject meet Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSMV ) criteria primary diagnosis ADHD base accept ADHD diagnostic instrument document subject 's medical record . Subject 's ADHD currently adequately control amphetaminebased product . 4 . Subject functioning age appropriate level intellectually , determine investigator . 5 . Must consider `` healthy '' . Healthy status define absence evidence active chronic disease ADHD follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , urinalysis . 6 . Ability swallow capsule investigational product whole . 1 . Current use ADHD medication amphetaminebased product . 2 . History hematological , hepatic , respiratory , cardiovascular , renal , neurological psychiatric disease , gall bladder removal , current recurrent disease ADHD 3 . Current relevant history physical psychiatric illness , medical disorder may require treatment 4 . Subject current , control uncontrolled , comorbid psychiatric diagnosis significant symptom 5 . Subject meet DSMV diagnosis conduct disorder . 6 . Subject consider suicide risk opinion investigator , previously make suicide attempt , currently demonstrate active suicidal ideation . 7 . Subject underweight base Centers Disease Control Prevention ( CDC ) body mass index ( BMI ) forage sexspecific value 8 . Subject significantly overweight base CDC BMIforage sex specific value 9 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem 10 . Subject concurrent chronic acute illness , disability , condition might confound result safety assessment conduct study 11 . Subject history seizure , chronic current tic disorder , current diagnosis Tourette 's Disorder . Subject history tic judge exclusionary . 12 . Subject 's blood pressure measurement exceed 90th percentile age , sex , height 13 . Subject known history hypertension . 14 . Subject know family history sudden cardiac death ventricular arrhythmia . 15 . Subject clinically significant ECG clinically significant laboratory abnormality 16 . Subject abnormal thyroid function 17 . Known suspected intolerance hypersensitivity investigational product ( ) , closelyrelated compound , ingredient . 18 . History alcohol substance abuse within last year . Subjects lifetime history amphetamine , cocaine , stimulant abuse and/or dependence exclude . 19 . Use Within 30 day prior first dose investigational product : used investigational product enrol clinical study ( include vaccine ) substantial change eat habit 20 . A positive screen alcohol drug abuse . A positive hepatitis B surface antigen ( HBsAg ) ; hepatitis C virus ( HCV ) ; HIV antibody screen . 21 . Use tobacco form last 30 day 22 . Prior screen failure , enrollment , participation study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>